|United States Of America||Published Application||170138956||05/18/2017||2015-017|
|Patent Cooperation Treaty||Published Application||WO2016070023||05/06/2016||2015-017|
The 4 dengue virus serotypes (DENV1-4) cause the most prevalent mosquito-borne viral illness in humans with up to 96 million cases annually worldwide. Dengue virus infections can result in a range of clinical manifestations from asymptomatic infection to dengue fever (DF) and the severe disease dengue hemorrhagic fever/dengue shock syndrome. Thus, there is a need for accurate, specific, inexpensive Dengue diagnostic test that can be used for early detection and treatment and can be used for surveillance and outbreak investigations.
UC Researchers have developed an assay that can be used to identify serotype-specific and cross-reactive B cells in DENV-infected individuals as well as in vaccines. The assay allows detection of B cell antigen specificity to the four different pathogen serotypes on a per-cell basis and allows visualization of serotype cross-reactivity versus type-specificity per cell.
The assay has been validated with both peripheral blood mononuclear cells from human DENV-immune individuals as well as serotype-specific and cross-reactive human monoclonal antibody hybridomas.
Dengue, DENV, diagnostic, infectious disease, Elispot, immunoassay, point of care, POC